REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that, based on a preliminary vote count provided by its proxy solicitors following its 2021 Annual Meeting of Stockholders,...
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the?Atlantic Coast Retina Club Macula 20/20 Annual Meeting
–44 week median follow up for patients (n=6)—-Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks post treatment—-Vision remains stable and anatomical improvements maintained– MENLO PARK, … […]
Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress
— Szil?rd Kiss, M.D. to present an encore presentation of data from first cohort of the OPTIC phase 1 trial of ADVM-022 in wet AMD — MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stag… […]
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular diseases, today announced that it will host a conference call and audio … […]